Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 4, 2011, Pages 625-629

  Johnson, J A ^a   Gong, L ^b   Whirl Carrillo, M ^b   Gage, B F ^c   Scott, S A ^d   Stein, C M ^e   Anderson, J L ^f   Kimmel, S E ^g   Lee, M T M ^h   Pirmohamed, M ⁱ   Wadelius, M ^j   Klein, T E ^b   Altman, R B ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b STANFORD UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f INTERMOUNTAIN HEALTHCARE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

ⁱ UNIVERSITY OF LIVERPOOL   (United Kingdom)

^j UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYP4F2 PROTEIN; CYTOCHROME P450 2C9; MENADIONE EPOXIDE; PROTEIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

AFRICAN AMERICAN; AGE; ALGORITHM; ANTICOAGULANT THERAPY; ASIAN; BODY SIZE; CAUCASIAN; CLINICAL PHARMACOLOGY; DOSING ALGORITHM; DRUG LABELING; DRUG MEGADOSE; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC SCREENING; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; NEGRO; OPTIMAL DRUG DOSE; PATIENT ATTITUDE; PHARMACOGENETICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC VARIATION; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC; WARFARIN;

EID: 80052962391     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.185     Document Type: Review

References (29)

1. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467 (2011).
2. Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. & Palareti, G.; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 160S-198S (2008). (Pubitemid 351892967)
3. Jacobs, L.G. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Clin. Geriatr. Med. 22, 17-32, vii (2006). (Pubitemid 41827956)
4. Rieder, M.J. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005). (Pubitemid 40740552)
5. Higashi, M.K. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002). (Pubitemid 34289221)
6. Shehab, N., Sperling, L.S., Kegler, S.R. & Budnitz, D.S. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Arch. Intern. Med. 170, 1926-1933 (2010).
7. Rost, S. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541 (2004). (Pubitemid 38209110)
8. Lee, C.R., Goldstein, J.A. & Pieper, J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12, 251-263 (2002). (Pubitemid 34596790)
9. Limdi, N.A. et al.; International Warfarin Pharmacogenetics Consortium. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115, 3827-3834 (2010).
10. Aithal, G.P., Day, C.P., Kesteven, P.J. & Daly, A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999). (Pubitemid 29103806)
11. Limdi, N.A. et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. 83, 312-321 (2008).
12. Lindh, J.D., Holm, L., Andersson, M.L. & Rane, A. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 65, 365-375 (2009).
13. Li, T., Chang, C.Y., Jin, D.Y., Lin, P.J., Khvorova, A. & Stafford, D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544 (2004). (Pubitemid 38209111)
14. Wajih, N., Hutson, S.M., Owen, J. & Wallin, R. Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle. J. Biol. Chem. 280, 31603-31607 (2005). (Pubitemid 41291905)
15. Wadelius, M. et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005). (Pubitemid 41131718)
16. Yuan, H.Y. et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751 (2005).
17. Gage, B.F. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331 (2008).
18. Klein, T.E. et al.; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
19. Scott, S.A., Edelmann, L., Kornreich, R. & Desnick, R.J. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am. J. Hum. Genet. 82, 495-500 (2008).
20. Wadelius, M. et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113, 784-792 (2009).
21. Gage, B.F. & Lesko, L.J. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J. Thromb. Thrombolysis 25, 45-51 (2008).
22. Finkelman, B.S., Gage, B.F., Johnson, J.A., Brensinger, C.M. & Kimmel, S.E. Genetic warfarin dosing: tables versus algorithms. J. Am. Coll. Cardiol. 57, 612-618 (2011).
23. C araco, Y., Blotnick, S. & Muszkat, M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. 83, 460-470 (2008). (Pubitemid 351272635)
24. Od, A. & Fahl, M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 325, 1073-1075 (2002).
25. Eckman, M.H., Rosand, J., Greenberg, S.M. & Gage, B.F. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Intern. Med. 150, 73-83 (2009).
26. Nowak-G?tl, U. et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood 116, 6101-6105 (2010).
27. Lenzini, P. et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin. Pharmacol. Ther. 87, 572-578 (2010).
28. Epstein, R.S. et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55, 2804-2812 (2010).
29. Ferder, N.S. et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J. Thromb. Haemost. 8, 95-100 (2010).